Robert L. Dood
( out of 774 reviews )

Robert L. Dood, MD, MSCE, BS

Languages spoken: English, Spanish

Clinical Locations

Primary Location

Sugar House Health Center

Women's Health Services
1280 E. Stringham Avenue
Salt Lake City , UT 84106
801-213-2995
Get Directions

Robert Dood, MD, MSCE is a gynecologic oncologist and assistant professor at the University of Utah School of Medicine and the Huntsman Cancer Institute. He specializes in the treatment of gynecologic pre-cancers and cancers of the ovary, uterus and endometrium, cervix, vulva, and vagina. His interests include screening and managing high risk and hereditary cancer populations including those with BRCA mutations and Lynch/HNPCC syndromes. He has a passion for fertility-sparing approaches in young women with cancer, pre-cancer, and hereditary syndromes, with special skills in hormonal approaches to endometrial cancer, uterus-sparing surgery for cervix cancer (trachelectomy), and sentinel lymph node evaluation of cervix and uterine cancers. His surgical expertise includes personalized approaches to cancer care, and minimally invasive approaches including both laparoscopic and robotic technologies.

His research interests include genetic testing of tumors for personalized medicine delivery, implementing enhanced recovery after surgery (ERAS) protocols, optimizing clinical and surgical outcomes, efficient survivorship models, with methods in implementation science and big data.

After completing his Bachelor of Science (BS) degree in Biochemistry from the University of Michigan with High Distinction, he attended the Perelman School of Medicine at the University of Pennsylvania where he received his Medical Doctorate (MD) and Master of Science in Clinical Epidemiology (MSCE) degrees. He completed his residency in Obstetrics and Gynecology at the Hospital of the University of Pennsylvania, and his research and clinical fellowship in Gynecologic Oncology at the University of Texas MD Anderson Cancer Center.

Specialties

Board Certification

American Board of Obstetrics & Gynecology (Obstetrics & Gynecology)
American Board of Obstetrics & Gynecology (Sub: Gynecologic Oncology)

Patient Rating

Patients consistently describe Dr. Dood as caring, compassionate, and professional, noting that he listens and puts them at ease. Reviewers praise his clear, thorough explanations of diagnoses and treatment options, which make complex information understandable and help them feel informed and confident. Comments also highlight attentive follow-up, coordination with the care team, and a respectful, reassuring office environment.

Generated via Patient Reviews

4.9 /5
( out of 774 reviews )

The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers. The scale on which responses are measured is 1 to 5 with 5 being the best score.

Robert Dood, MD, MSCE is a gynecologic oncologist and assistant professor at the University of Utah School of Medicine and the Huntsman Cancer Institute. He specializes in the treatment of gynecologic pre-cancers and cancers of the ovary, uterus and endometrium, cervix, vulva, and vagina. His interests include screening and managing high risk and hereditary cancer populations including those with BRCA mutations and Lynch/HNPCC syndromes. He has a passion for fertility-sparing approaches in young women with cancer, pre-cancer, and hereditary syndromes, with special skills in hormonal approaches to endometrial cancer, uterus-sparing surgery for cervix cancer (trachelectomy), and sentinel lymph node evaluation of cervix and uterine cancers. His surgical expertise includes personalized approaches to cancer care, and minimally invasive approaches including both laparoscopic and robotic technologies.

His research interests include genetic testing of tumors for personalized medicine delivery, implementing enhanced recovery after surgery (ERAS) protocols, optimizing clinical and surgical outcomes, efficient survivorship models, with methods in implementation science and big data.

After completing his Bachelor of Science (BS) degree in Biochemistry from the University of Michigan with High Distinction, he attended the Perelman School of Medicine at the University of Pennsylvania where he received his Medical Doctorate (MD) and Master of Science in Clinical Epidemiology (MSCE) degrees. He completed his residency in Obstetrics and Gynecology at the Hospital of the University of Pennsylvania, and his research and clinical fellowship in Gynecologic Oncology at the University of Texas MD Anderson Cancer Center.

Board Certification and Academic Information

Academic Departments Obstetrics & Gynecology -Assistant Professor (Clinical)
Academic Divisions Gynecological Oncology
Board Certification
American Board of Obstetrics & Gynecology (Obstetrics & Gynecology)
American Board of Obstetrics & Gynecology (Sub: Gynecologic Oncology)

Selected Publications

Journal Article

  1. Dood RL, Zhao Y, Armbruster SD, Coleman RL, Tworoger S, Sood AK, Baggerly KA (2018). Defining Survivorship Trajectories Across Patients with Solid Tumors: An Evidence-Based Approach. JAMA Oncol, 4(11), 1519-1526.
  2. Dood RL, Fleming ND, Coleman RL, Westin SN, Lara OD, LaFargue CJ, Liu J, Sood AK (2018). When Ovarian Cancer Is Not: Characterizing Nonovarian Cancer Pathology in a Laparoscopy-Based Triage System. Int J Gynecol Cancer, 28(8), 1485-1490.
  3. Nagaraja AS, Dood RL, Armaiz-Pena G, Kang Y, Wu SY, Allen JK, Jennings NB, Mangala LS, Pradeep S, Lyons Y, Haemmerle M, Gharpure KM, Sadaoui NC, Rodriguez-Aguayo C, Ivan C, Wang Y, Baggerly K, Ram P, Lopez-Berestein G, Liu J, Mok SC, Cohen L, Lutgendorf SK, Cole SW, Sood AK (2018). Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens. JCI Insight, 3(11).
  4. Huang Y, Hu W, Huang J, Shen F, Sun Y, Ivan C, Pradeep S, Dood R, Haemmerle M, Jiang D, Mangala LS, Noh K, Hansen JM, Dalton HJ, Previs RA, Nagaraja AS, McGuire M, Jennings NB, Broaddus R, Coleman RL, Sood AK (2017). Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer. Mol Cancer Ther, 17(2), 464-473.
  5. Lyons YA, Pradeep S, Wu SY, Haemmerle M, Hansen JM, Wagner MJ, Villar-Prados A, Nagaraja AS, Dood RL, Previs RA, Hu W, Zhao Y, Mak DH, Xiao Z, Melendez BD, Lizee GA, Mercado-Uribe I, Baggerly KA, Hwu P, Liu J, Overwijk WW, Coleman RL, Sood AK (2017). Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy. Oncotarget, 8(57), 96496-96505.
  6. Haemmerle M, Taylor ML, Gutschner T, Pradeep S, Cho MS, Sheng J, Lyons YM, Nagaraja AS, Dood RL, Wen Y, Mangala LS, Hansen JM, Rupaimoole R, Gharpure KM, Rodriguez-Aguayo C, Yim SY, Lee JS, Ivan C, Hu W, Lopez-Berestein G, Wong ST, Karlan BY, Levine DA, Liu J, Afshar-Kharghan V, Sood AK (2017). Platelets reduce anoikis and promote metastasis by activating YAP1 signaling. Nat Commun, 8(1), 310.
  7. Nagaraja AS, Dood RL, Armaiz-Pena G, Kang Y, Wu SY, Allen JK, Jennings NB, Mangala LS, Pradeep S, Lyons Y, Haemmerle M, Gharpure KM, Sadaoui NC, Rodriguez-Aguayo C, Ivan C, Wang Y, Baggerly K, Ram P, Lopez-Berestein G, Liu J, Mok SC, Cohen L, Lutgendorf SK, Cole SW, Sood AK (2017). Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens. JCI Insight, 2(16).
  8. Sans M, Gharpure K, Tibshirani R, Zhang J, Liang L, Liu J, Young JH, Dood RL, Sood AK, Eberlin LS (2017). Metabolic Markers and Statistical Prediction of Serous Ovarian Cancer Aggressiveness by Ambient Ionization Mass Spectrometry Imaging. Cancer Res, 77(11), 2903-2913.
  9. Dood RL, Gracia CR, Sammel MD, Haynes K, Senapati S, Strom BL (2014). Endometrial cancer after endometrial ablation vs medical management of abnormal uterine bleeding. J Minim Invasive Gynecol, 21(5), 744-52.

Letter

  1. Dood RL (2014). Reply: To PMID 24590007. [Letter to the editor]. J Minim Invasive Gynecol, 22(3), 510.